Schreier, S.; Budchart, P.; Borwornpinyo, S.; Adireklarpwong, L.; Chirappapha, P.; Triampo, W.; Lertsithichai, P. Cancer-associated Systemic Abnormality: A Novel Marker Panel for Early-stage Breast Cancer Characterization. Preprints2024, 2024020681. https://doi.org/10.20944/preprints202402.0681.v1
APA Style
Schreier, S., Budchart, P., Borwornpinyo, S., Adireklarpwong, L., Chirappapha, P., Triampo, W., & Lertsithichai, P. (2024). Cancer-associated Systemic Abnormality: A Novel Marker Panel for Early-stage Breast Cancer Characterization. Preprints. https://doi.org/10.20944/preprints202402.0681.v1
Chicago/Turabian Style
Schreier, S., Wannapong Triampo and Panuwat Lertsithichai. 2024 "Cancer-associated Systemic Abnormality: A Novel Marker Panel for Early-stage Breast Cancer Characterization" Preprints. https://doi.org/10.20944/preprints202402.0681.v1
Abstract
Background: Circulating rare cells participate in breast cancer evolution as systemic components of the disease and thus, are a source of theranostic information. Exploration of cancer-associated rare cells is in its infancy. We determined the validity of a rare-cell detection platform and demonstrated the usefulness of a certain rare cell subset as a novel approach to characterize the breast cancer system. Methods: Linearity of the Rarmax® platform was established using a spike-in approach. The platform includes red blood cell lysis, leukocyte depletion and high-resolution fluorescence image recording. Rare cell analysis was conducted on 28 samples (before and after surgery) from 14 patients with breast cancer, 20 healthy volunteers and 9 non-cancer control volunteers. In-depth identification of rare cells, including circulating tumor cells, endothelial-like cells, erythroblasts and inflammation-associated cells, was performed using a phenotype and morphology-based classification system. Results: The platform performed linearly over a range of 5-950 spiked cells, with an average recovery of 84.6%. Circulating epithelial and endothelial-like cell subsets have been demonstrated to be associated with or independent of cancer with tumor presence. Furthermore, certain cell patterns may be associated with treatment-related adverse effects. The sensitivity in detecting tumor-presence and cancer-associated abnormality before surgery was 50% and 85.7%, respectively and the specificity was 100% and 96.6%, respectively. Conclusion: The present study supports the idea of a cancer-associated rare cell abnormality to represent tumor entities as well as systemic cancer. The latter is independent of the apparent clinical cancer.
Medicine and Pharmacology, Pathology and Pathobiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
